OXIGENE, INC.

Company

Oncotelic Therapeutics, Inc.

Filed

February 18, 2011

Period of Report

March 18, 2011

Accession Number

0000950123-11-015688

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →